Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity

A method of using sigma (σ) receptor ligands, said method comprising the steps of:

• providing a compound comprising a sigma (σ)-receptor ligands and a sigma (σ) ligands generics, said sigma (σ) ligands generics being selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole;
• and
• using said compound for preparation of pharmaceuticals with anticancer, antimetastatic and antiviral activity associated with analgesic properties.

A method of using sigma (σ) receptor ligands, said method comprising the steps of:

• providing a compound comprising a sigma (σ)-receptor ligands and a sigma (σ) ligands generics, said sigma (σ) ligands generics being selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole;
• and
• using said compound for preparation of pharmaceuticals with analgesic activity against neuropathic pain.

A method of dosing for protective activity against the pathogenesis of inflammatory and neuropathic pain with sigma (σ) receptor ligands, said method comprising the steps of administering a sigma (σ)-receptor ligands and a sigma (σ) ligands generics selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole.

A method of dosing for protective activity against the pathogenesis of inflammatory and neuropathic pain with sigma (σ) receptor ligands, said method comprising the step of administering a sigma (σ)-receptor ligand and a compound selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole.